In this study, wide variations in ampicillin-sulbactam pharmacokinetics (~80 %) were observed among hospitalised patients and the final pharmacokinetics model established serum creatinine as the covariate to describe the clearance of ampicillin-sulbactam in our patient cohort.

The highest dose in the approved product information may be required to achieve target exposure, particularly for hospitalised patients with preserved renal function infected with less susceptible causative pathogens.